Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) and Surrozen (NASDAQ:SRZN – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.
Valuation & Earnings
This table compares Prelude Therapeutics and Surrozen”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prelude Therapeutics | $12.14 million | 21.23 | -$99.50 million | ($0.73) | -4.42 |
| Surrozen | $3.48 million | 79.23 | -$242.03 million | ($40.55) | -0.59 |
Profitability
This table compares Prelude Therapeutics and Surrozen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prelude Therapeutics | N/A | -75.35% | -44.39% |
| Surrozen | -2,885.33% | N/A | -93.62% |
Risk & Volatility
Prelude Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Prelude Therapeutics and Surrozen, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prelude Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Surrozen | 1 | 1 | 4 | 1 | 2.71 |
Prelude Therapeutics presently has a consensus price target of $8.75, indicating a potential upside of 170.90%. Surrozen has a consensus price target of $48.33, indicating a potential upside of 103.51%. Given Prelude Therapeutics’ higher probable upside, research analysts plainly believe Prelude Therapeutics is more favorable than Surrozen.
Institutional & Insider Ownership
79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Prelude Therapeutics beats Surrozen on 10 of the 14 factors compared between the two stocks.
About Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
